• Ovarian aging is a biologically programmed and progressive decline in both the quantity and quality of ovarian follicles — the microscopic structures that contain a woman’s eggs. At birth, females have approximately 1–2 million primordial follicles, but by puberty only about 300,000–500,000 remain. With each menstrual cycle, a cohort of follicles is recruited, and the majority undergo atresia (degeneration). By age 30, the average ovarian reserve falls to roughly 12% of peak levels, and by age 40 it drops below 3%. This decline is reflected in measurable biomarkers such as Anti-Müllerian Hormone (AMH) and Antral Follicle Count (AFC) on ultrasound, both of which decrease steadily with age. As ovarian reserve diminishes, fecundity decreases, time to pregnancy increases, and miscarriage risk rises due to increasing rates of chromosomal abnormalities in oocytes.The mechanisms driving ovarian aging are multifactorial. Genomic instability, oxidative stress, mitochondrial dysfunction, telomere shortening, and impaired DNA repair capacity all contribute to accelerated follicle loss and declining oocyte quality. Mitochondria — the energy-producing organelles inside every cell — are particularly critical because oocytes require high ATP levels for maturation and embryonic development. Studies show that aged oocytes have reduced mitochondrial DNA copy numbers and increased mitochondrial DNA mutations, which correlate with poor fertilization and embryo arrest. Inflammatory cytokines and systemic metabolic factors — such as insulin resistance — further exacerbate ovarian aging by promoting stromal fibrosis and disrupting local signaling needed for follicle recruitment.From a clinical perspective, younger women under 35 with diminished ovarian reserve (DOR) may still produce high-quality oocytes despite reduced numbers, whereas women over 40 face both numerical and qualitative challenges. Data from Assisted Reproductive Technology (ART) registries show that live birth rates decline sharply after age 35 and drop below 5% per cycle by age 42 with one’s own eggs. With advancing age, blastocyst formation rates, implantation rates, and euploid embryo rates all decrease dramatically. For example, preimplantation genetic testing (PGT) data reveal that the proportion of chromosomally normal embryos in women aged 25–30 is approximately 40–50%, whereas in women 40+ it may be as low as 5–10%. These trends emphasize that both depletion of the follicle pool and compromised genomic integrity significantly undermine fertility potential with age.

  Projections based on large cohort studies and fertility clinic outcomes suggest that interventions aimed at modifying the ovarian microenvironment — rather than simply relying on exogenous hormones — may be necessary to shift the fertility trajectory, especially in women with premature ovarian insufficiency or poor ovarian response to stimulation. While traditional ART addresses egg retrieval and embryo transfer, it does not counteract the fundamental cellular deficits associated with ovarian aging. Emerging research in regenerative medicine — including stem cell therapy, growth factor modulation, and mitochondrial support — aims to improve not only measurable biomarkers (like AMH or AFC) but also oocyte developmental competence. Early clinical evidence indicates that such interventions may delay ovarian aging, restore endocrine balance, and enhance responsiveness to ovarian stimulation, though large-scale randomized trials are still needed to validate long-term reproductive outcomes.

Mechanism of Action

Platelet-Rich Plasma (PRP) therapy for ovarian rejuvenation is based on the principle that platelets are natural reservoirs of regenerative signaling molecules. PRP is obtained from the patient’s own peripheral blood through centrifugation, which concentrates platelets to levels typically 3–7 times above baseline. Once activated, these platelets release a complex cocktail of growth factors, cytokines, chemokines, and bioactive proteins that influence tissue repair and cellular activation.

The key components of PRP include:

• PDGF (Platelet-Derived Growth Factor) – promotes cellular proliferation and tissue remodeling
• VEGF (Vascular Endothelial Growth Factor) – stimulates angiogenesis and improves ovarian blood supply
• TGF-β (Transforming Growth Factor Beta) – regulates extracellular matrix repair and cellular differentiation
• IGF-1 (Insulin-Like Growth Factor-1) – enhances granulosa cell survival and follicular responsiveness

When PRP is injected directly into ovarian cortical tissue, it initiates a localized regenerative cascade. VEGF-driven angiogenesis improves microvascular density, enhancing oxygen and nutrient delivery to dormant follicles. PDGF and IGF-1 stimulate stromal cell proliferation and support granulosa cell function, which is critical for estrogen production and follicular maturation. TGF-β contributes to remodeling fibrotic areas of ovarian stroma, creating a more favorable microenvironment for follicle recruitment.

At the molecular level, PRP is believed to activate the PI3K/AKT signaling pathway, a key regulator of primordial follicle awakening. This pathway promotes follicular survival and inhibits apoptosis (programmed cell death). By improving mitochondrial efficiency and reducing oxidative stress within ovarian tissue, PRP may also enhance oocyte metabolic competence.

---

Biological Effects on Ovarian Tissue

After PRP administration, several sequential biological processes occur:

1. Inflammatory Modulation Phase (First 1–2 weeks)
   A controlled, localized inflammatory response is triggered, which recruits reparative immune cells and stimulates tissue regeneration.
2. Angiogenic Phase (Weeks 2–6)
   Increased VEGF activity enhances capillary formation, improving ovarian perfusion and restoring stromal vitality.
3. Follicular Recruitment Phase (1–3 months)
   Dormant primordial follicles may be activated, leading to measurable increases in antral follicle count (AFC).
4. Endocrine Improvement Phase (3–6 months)
   Enhanced granulosa cell function may lead to improved estradiol production, stabilization of menstrual cycles, and possible increases in AMH levels.

---

Clinical Outcomes and Effectiveness

Emerging clinical data suggest that PRP ovarian rejuvenation may provide measurable benefits in selected patient populations:

• AMH increase reported in 30–40% of patients, particularly in women under 40 with diminished ovarian reserve (DOR)
• Reduction in FSH levels in some premature ovarian insufficiency (POI) cases
• Return of menstruation in a subset of POI patients within 1–3 months
• Improved oocyte yield during IVF cycles, with some studies showing increased number of retrieved mature oocytes

However, results are heterogeneous and strongly dependent on baseline ovarian reserve. Women with detectable AMH and residual follicles respond more favorably than those with complete ovarian failure.

---

Best Candidates for PRP Ovarian Therapy

PRP tends to be most effective in:

• Women under 40 with diminished ovarian reserve
• Poor responders to IVF stimulation
• Early-stage POI with residual follicular activity
• Women seeking to enhance ovarian responsiveness prior to ART

In contrast, patients with severely fibrotic ovarian tissue or undetectable ovarian reserve may experience limited benefit.

---

Advantages of PRP Therapy

• Autologous (minimal immunologic risk)
• Minimally invasive
• Outpatient procedure
• Low complication rate
• Can be combined with stem cell therapy or exosome therapy

---

Limitations and Considerations

While PRP shows promise, it is important to emphasize that:

• Standardized preparation protocols vary
• Large randomized controlled trials are still limited
• Not all patients experience hormonal improvement
• PRP does not “create” new eggs — it aims to optimize the existing follicular pool

---

Summary

PRP ovarian rejuvenation represents a biologically plausible and increasingly utilized regenerative strategy aimed at enhancing ovarian microenvironment, improving vascularization, and activating dormant follicles. Clinical evidence indicates moderate effectiveness, particularly in younger women with residual ovarian reserve. Although not a universal solution for infertility, PRP may serve as a valuable adjunct in personalized fertility restoration programs, especially when combined with other regenerative modalities.

Mechanism of Action

Exosome ovarian therapy is an advanced regenerative approach that utilizes extracellular vesicles (30–150 nm in size) secreted by stem cells. Unlike whole-cell therapy, exosomes contain no living cells but carry highly active biological cargo capable of reprogramming damaged tissue at the molecular level.

Exosomes derived from mesenchymal stem cells (MSCs) contain:

• MicroRNAs (miRNA-21, miRNA-146a, miRNA-126 and others)
• Messenger RNA (mRNA)
• Growth factors
• Anti-inflammatory cytokines
• Proteins involved in cellular repair
• Lipid signaling molecules

When administered into ovarian tissue, exosomes act as biological messengers, transferring regenerative instructions to granulosa cells, stromal cells, endothelial cells, and possibly dormant follicular niches.

---

Cellular and Molecular Pathways

Exosome therapy influences ovarian rejuvenation through several critical intracellular signaling pathways:

1. Activation of PI3K/AKT Pathway

This pathway regulates primordial follicle survival and growth. Exosomal miRNAs can suppress PTEN (a negative regulator of follicle activation), thereby allowing controlled activation of dormant follicles.

2. Modulation of mTOR Signaling

mTOR regulates cellular metabolism and growth. Controlled activation supports follicular development without excessive depletion of the follicle pool.

3. Anti-Apoptotic Effects

Exosomes increase expression of Bcl-2 (anti-apoptotic protein) and reduce Bax expression (pro-apoptotic protein), protecting granulosa cells from programmed cell death.

4. Reduction of Oxidative Stress

Exosomal cargo enhances antioxidant enzyme activity (SOD, catalase, glutathione peroxidase), decreasing reactive oxygen species (ROS) that contribute to oocyte aging.

5. Angiogenesis Enhancement

Through VEGF and miRNA-126 signaling, exosomes promote microvascular repair and improve ovarian perfusion.

---

Impact on the Ovarian Microenvironment

Exosomes primarily work by restoring the ovarian niche rather than directly “creating” new follicles. Their regenerative influence includes:

• Reduction of stromal fibrosis
• Suppression of chronic inflammatory cytokines (TNF-α, IL-6)
• Increase of anti-inflammatory cytokines (IL-10)
• Improved granulosa cell proliferation
• Enhanced communication between oocytes and surrounding support cells

By stabilizing the ovarian microenvironment, exosome therapy creates favorable conditions for existing primordial follicles to resume development.

---

Biological Stages After Exosome Therapy

Stage 1 (Weeks 1–3): Immunomodulation and Anti-Inflammatory Response
Exosomes reduce inflammatory signaling and improve stromal cellular communication.

Stage 2 (Weeks 3–8): Vascular and Stromal Repair
Enhanced angiogenesis improves oxygen and nutrient supply to follicles.

Stage 3 (Months 2–4): Follicular Recruitment
Improved signaling leads to increased antral follicle count in responsive patients.

Stage 4 (Months 4–6): Endocrine Stabilization
Estradiol production may improve, FSH levels may decrease, and menstrual cycles may normalize.

---

Clinical Outcomes and Effectiveness

While still emerging, early clinical data and observational studies report promising trends:

• AMH improvement in 30–55% of patients, particularly in early-stage diminished ovarian reserve
• Increase in antral follicle count (AFC) within 2–4 months
• Improved ovarian response during IVF stimulation
• Restoration of menstruation in selected POI patients
• Potential improvement in embryo quality in some cases

Compared to PRP, exosome therapy may provide more sustained molecular signaling due to targeted miRNA delivery and stronger anti-inflammatory effects.

---

Best Candidates for Exosome Ovarian Therapy

Exosome therapy may be particularly beneficial for:

• Women with early premature ovarian insufficiency
• Patients with chronic inflammatory ovarian damage
• Women 35–42 with declining ovarian reserve
• Poor IVF responders with preserved but dysfunctional follicles

Women with completely depleted follicle pools or advanced ovarian fibrosis may have limited responsiveness.

---

Advantages of Exosome Therapy

• Cell-free therapy (lower theoretical immunologic risk)
• No risk of uncontrolled cell proliferation
• Strong anti-inflammatory and anti-apoptotic properties
• Can be combined with PRP or MSC therapy
• Potentially safer regulatory profile compared to whole-cell transplantation

---

Comparison with PRP

Feature	PRP	Exosomes
Source	Autologous blood	Stem cell-derived vesicles
Main Effect	Growth factor release	Molecular signaling via miRNA
Anti-inflammatory power	Moderate	Strong
Angiogenesis	Yes	Yes
Cellular reprogramming	Limited	Significant
Duration of signaling	Shorter	Potentially longer

---

Summary

Exosome ovarian therapy represents a next-generation regenerative strategy focused on precision molecular signaling rather than simple growth factor stimulation. By reducing inflammation, preventing apoptosis, improving mitochondrial function, and activating key follicular pathways, exosomes may enhance ovarian function in selected patients.

Although still evolving, exosome therapy shows meaningful potential in improving ovarian reserve markers, follicular responsiveness, and endocrine stability — particularly in women with early-stage ovarian decline or inflammatory-related dysfunction.

Mesenchymal Stem Cell (MSC) ovarian therapy is one of the most extensively studied regenerative approaches for restoring ovarian function. MSCs are multipotent stromal cells capable of differentiating into various cell types and, more importantly, secreting a wide spectrum of bioactive molecules that support tissue repair, angiogenesis, immunomodulation, and anti-apoptotic protection.

MSCs used in ovarian therapy are commonly derived from:

• Bone marrow
• Adipose tissue
• Umbilical cord (Wharton’s jelly)
• Placental tissue

These cells are typically administered via intra-ovarian injection or intravenous infusion, depending on the treatment protocol and clinical objective.

---

Mechanism of Action

Unlike hormonal stimulation, which temporarily drives follicular growth, MSC therapy aims to restore the ovarian microenvironment at the structural and molecular level.

1. Paracrine Signaling (Primary Mechanism)

The majority of MSC effects are mediated through paracrine secretion rather than direct differentiation. MSCs release:

• VEGF (vascular endothelial growth factor)
• HGF (hepatocyte growth factor)
• IGF-1
• Basic fibroblast growth factor (bFGF)
• Anti-inflammatory cytokines
• Exosomes and extracellular vesicles

These molecules act locally to repair stromal tissue and improve follicular viability.

---

2. Angiogenesis and Microvascular Restoration

Ovarian aging and damage often involve reduced blood flow and stromal hypoxia. MSCs increase VEGF expression, promoting:

• Capillary density expansion
• Improved oxygen delivery
• Enhanced nutrient supply to follicles

Improved vascularization is directly linked to better follicle survival and oocyte maturation.

---

3. Anti-Apoptotic and Cytoprotective Effects

One of the central problems in ovarian insufficiency is excessive apoptosis (programmed cell death) of granulosa cells.

MSCs:

• Upregulate anti-apoptotic proteins (Bcl-2)
• Downregulate pro-apoptotic markers (Bax, caspase-3)
• Reduce oxidative stress via antioxidant enzyme activation

This preserves existing follicles and improves their developmental competence.

---

4. Activation of Dormant Follicles

MSC therapy influences key intracellular pathways:

• PI3K/AKT signaling activation
• Controlled mTOR pathway modulation
• Suppression of PTEN-mediated inhibition

These pathways regulate primordial follicle recruitment, potentially awakening dormant follicles without causing premature depletion.

---

5. Immunomodulation

In cases of autoimmune-related premature ovarian insufficiency (POI), MSCs suppress abnormal immune responses by:

• Reducing pro-inflammatory cytokines (TNF-α, IL-6)
• Increasing anti-inflammatory mediators (IL-10)
• Modulating T-cell activity

This creates a more stable endocrine and ovarian environment.

---

Cellular-Level Biochemical Processes

At the cellular scale, MSC therapy:

• Enhances mitochondrial biogenesis in granulosa cells
• Improves ATP production in oocytes
• Reduces reactive oxygen species (ROS)
• Decreases stromal fibrosis
• Promotes extracellular matrix remodeling

Mitochondrial function is particularly critical in women over 40, where energy deficiency contributes to poor embryo development.

---

Clinical Applications

MSC ovarian therapy has been investigated in:

• Premature ovarian insufficiency (POI)
• Chemotherapy-induced ovarian damage
• Diminished ovarian reserve (DOR)
• Poor ovarian response in IVF
• Age-related ovarian decline

---

Biological Stages After MSC Therapy

Stage 1: Anti-Inflammatory Reset (Weeks 1–3)

Reduction of inflammatory cytokines and stromal repair begins.

Stage 2: Angiogenic Remodeling (Weeks 3–8)

Improved blood flow and stromal oxygenation.

Stage 3: Follicular Activation (Months 2–4)

Increase in antral follicle count (AFC) in responsive patients.

Stage 4: Hormonal Regulation (Months 3–6)

Possible rise in AMH, reduction in FSH, improved estradiol production.

Stage 5: Functional Ovarian Response (Months 4–9)

Improved oocyte yield during IVF stimulation cycles.

---

Clinical Effectiveness

Although large randomized trials are ongoing, early data and observational studies suggest:

• Hormonal improvement in approximately 50–70% of women with POI
• Return of menstruation in 40–60% of selected POI patients
• Increase in antral follicle count in DOR cases
• Improved oocyte retrieval numbers in IVF cycles
• Occasional reports of spontaneous pregnancy

Results are significantly better in women with residual ovarian reserve compared to complete ovarian atrophy.

---

Effectiveness by Patient Group

Women Under 40

• Higher regenerative capacity
• Better follicular responsiveness
• Greater AMH improvement potential

Women 40+

• More variable outcomes
• Stronger benefit when combined with PRP or exosome therapy
• Primary improvement often seen in ovarian response rather than dramatic AMH rise

---

Advantages of MSC Ovarian Therapy

• Multi-pathway regenerative effect
• Strong immunomodulatory properties
• Potential benefit in chemotherapy-induced damage
• Can be combined with other regenerative approaches
• Longer-lasting paracrine signaling compared to PRP

---

Limitations and Considerations

• Standardization of cell dose and source varies
• Long-term reproductive outcome data still evolving
• Regulatory frameworks differ by country
• Not effective in cases of complete follicular depletion

MSC therapy aims to optimize and preserve existing follicles — it does not create new oocytes.

---

Comparison with PRP and Exosomes

Feature	PRP	Exosomes	MSCs
Growth factors	Moderate	Moderate	High
Anti-inflammatory effect	Mild	Strong	Very strong
Stromal repair	Limited	Moderate	Significant
Follicle activation	Moderate	Moderate	Strong
Duration of effect	Short	Medium	Longer
Suitable for severe POI	Limited	Moderate	More promising

---

Summary

Mesenchymal Stem Cell ovarian therapy represents one of the most comprehensive regenerative approaches in fertility medicine. By restoring stromal integrity, enhancing angiogenesis, modulating immune activity, and activating key follicular pathways, MSCs target the fundamental biological drivers of ovarian aging and dysfunction.

While not a guaranteed cure for infertility, MSC therapy offers a biologically rational strategy to improve ovarian responsiveness, hormonal balance, and reproductive potential — especially in women with diminished ovarian reserve, premature ovarian insufficiency, or post-chemotherapy ovarian damage.

Induced pluripotent stem cells (iPSCs) represent one of the most advanced and experimental frontiers in reproductive regenerative medicine. Unlike mesenchymal stem cells (MSCs), which primarily act through paracrine signaling, iPSCs possess true pluripotency — the ability to differentiate into nearly any cell type in the body. They are created by reprogramming adult somatic cells (such as skin fibroblasts or blood cells) back into an embryonic-like state through the introduction of specific transcription factors (commonly OCT4, SOX2, KLF4, and c-MYC).

In ovarian regeneration, iPSC technology aims not only to improve the ovarian microenvironment but potentially to restore or replace damaged ovarian cell populations, including granulosa-like cells, theca-like cells, and, in experimental settings, even germ cell–like structures.

It is important to emphasize that iPSC applications in fertility medicine remain largely preclinical and investigational, with most data derived from laboratory and animal models rather than large-scale human trials.

---

Mechanisms of Action in Ovarian Tissue

1. Differentiation into Ovarian Support Cells

One of the most promising applications of iPSCs is their differentiation into:

• Granulosa-like cells
• Theca-like cells
• Ovarian stromal cells

Granulosa cells are essential for oocyte survival and estrogen production. In ovarian insufficiency, granulosa dysfunction leads to impaired follicle maturation and hormonal imbalance. Laboratory studies demonstrate that iPSC-derived granulosa-like cells can:

• Produce estradiol
• Express FSH receptors
• Support follicle-like structures in vitro

This suggests potential for restoring endocrine support in damaged ovaries.

---

2. Germ Cell-Like Differentiation 

In clinical models, researchers have successfully differentiated iPSCs into primordial germ cell-like cells (PGCLCs). These cells resemble early germline precursors and, in some experimental settings, have contributed to the formation of oocyte-like structures.

It opens a  pathway toward:

• Replenishing severely depleted ovarian reserves
• Generating new follicular structures
• Reconstructing ovarian tissue in cases of complete failure

This application remains highly experimental and requires strict regulatory oversight.

---

3. Ovarian Niche Reconstruction

Beyond differentiation, iPSCs may contribute to ovarian regeneration by:

• Enhancing stromal repair
• Reducing fibrosis
• Promoting angiogenesis
• Supporting extracellular matrix remodeling

When introduced into ovarian tissue (in preclinical models), iPSCs can secrete growth factors and cytokines similar to MSCs, but with potentially broader differentiation potential.

---

Molecular and Biochemical Pathways

iPSC-derived cells influence several key biological pathways:

PI3K/AKT Pathway Activation

Supports follicle survival and reduces apoptosis.

Wnt/β-Catenin Signaling

Plays a critical role in ovarian follicle development and granulosa cell proliferation.

mTOR Regulation

Controls follicular activation and cellular metabolism.

FOXL2 and GATA4 Expression

Markers essential for granulosa cell identity and ovarian differentiation.

Additionally, iPSC-derived cells may restore mitochondrial function and ATP production in damaged ovarian environments, which is particularly relevant for women over 40 experiencing age-related mitochondrial decline.

---

Potential Clinical Applications

Although still investigational, iPSC ovarian applications may target:

• Severe premature ovarian insufficiency (POI)
• Chemotherapy-induced ovarian failure
• Genetic ovarian dysfunction
• Complete follicular depletion (future potential)
• Endocrine restoration in early menopause

In theory, iPSCs could offer regenerative possibilities beyond what PRP, exosomes, or MSCs can achieve, particularly in advanced ovarian damage.

---

Advantages of iPSC Technology

• True pluripotency (ability to generate multiple ovarian cell types)
• Autologous potential (patient-derived cells reduce immune rejection risk)
• Potential to regenerate endocrine and structural components
• Future possibility of germline reconstruction

---

Comparison with Other Regenerative Methods

Feature	PRP	Exosomes	MSCs	iPSCs
Growth factor stimulation	Yes	Yes	Yes	Yes
Anti-inflammatory effect	Moderate	Strong	Very strong	Moderate
Structural tissue repair	Limited	Moderate	Strong	Potentially very strong
Cell replacement potential	No	No	Limited	Yes
Germ cell generation	No	No	No	Yes
Clinical maturity	Emerging	Emerging	Most studied	Most studied

 

---

Summary

Induced pluripotent stem cell (iPSC) technology represents the most advanced and transformative — yet still experimental — approach in ovarian regenerative medicine. Unlike PRP or MSC therapy, which primarily enhance existing ovarian tissue, iPSCs hold the theoretical potential to rebuild ovarian cellular architecture, restore endocrine function, and possibly contribute to germ cell development.

While current applications remain largely preclinical, iPSC research signals a future in which ovarian failure may not simply be managed, but biologically reconstructed. Continued clinical trials and strict safety validation will determine how and when this powerful technology enters mainstream reproductive medicine.

Ovarian Rejuvenation Regenerative Treatment Protocol

Ovarian aging, diminished ovarian reserve, and premature ovarian insufficiency are complex conditions characterized by reduced follicular count, impaired oocyte quality, hormonal imbalances, and compromised ovarian microenvironment. Traditional therapies, such as hormone replacement or fertility drugs, often focus on symptom management, while regenerative medicine aims to restore ovarian function at the cellular and tissue level.

Our treatment protocol employs a comprehensive regenerative approach combining advanced cellular therapies, exosome-based interventions, platelet-rich plasma (PRP), and iPSC-derived ovarian support cells. The goal is to promote follicular survival, improve hormonal regulation, restore ovarian microenvironment, and enhance fertility potential.

---

Diagnostic Evaluation

Prior to treatment, patients undergo an in-depth diagnostic assessment to identify mechanisms contributing to ovarian dysfunction.

Results of these diagnostics guide the individualization of the regenerative therapy plan.

---

Regenerative Treatment Components

Each component targets mechanisms underlying ovarian aging, including follicular loss, microvascular insufficiency, oxidative stress, and hormonal imbalance.

---

Ovarian Microenvironment Restoration

A core goal of the protocol is restoring the ovarian microenvironment, encompassing vascular integrity, extracellular matrix balance, immune signaling, and follicular niche support.

Chronic oxidative stress, fibrosis, and inflammation can disrupt follicular maturation and oocyte quality. Regenerative therapies aim to recreate a physiological environment conducive to follicular development, hormonal regulation, and reproductive function.

---

Hormonal and Metabolic Support

The protocol may include supportive interventions to optimize endocrine function, mitochondrial efficiency, and overall ovarian metabolism.

Proper regulation of estrogen, progesterone, AMH, and other reproductive hormones is essential for follicular survival and oocyte maturation. Supporting metabolic and hormonal pathways enhances the effectiveness of regenerative therapies.

---

Treatment Process

---

Integrated Regenerative Approach

The guiding principle of this protocol is combination therapy, where multiple regenerative technologies act synergistically to address ovarian inflammation, follicular loss, microvascular impairment, and hormonal/metabolic imbalance.

By simultaneously targeting these mechanisms, the treatment aims to restore ovarian function, improve hormonal profiles, enhance follicular survival, and support fertility potential.

The cost of regenerative therapy for ovarian rejuvenation may vary depending on several factors, including the severity of ovarian aging, the patient’s hormonal profile, ovarian reserve, and the specific combination of regenerative therapies used in the treatment protocol.

Since each case is unique, our clinic follows a personalized approach, where the therapy plan is individually developed based on diagnostic findings, medical history, and the biological characteristics of ovarian function.

The protocol may include various types of regenerative therapies, such as mesenchymal stem cells (MSC), induced pluripotent stem cells (iPSC)-derived ovarian support cells, exosome treatments, and platelet-rich plasma (PRP), aimed at restoring the ovarian microenvironment, improving follicular survival, enhancing angiogenesis, and optimizing hormonal balance.

Due to this individualized and multidisciplinary approach, the total cost of therapy typically ranges from €6,000 to €10,000, depending on the treatment strategy and the number of regenerative components included in the program.

Some medical articles about ovarian rejuvenation :

• “Exosomes derived from mesenchymal stem cells repair ovarian function by suppressing NLRP3-mediated pyroptosis in cyclophosphamide-induced premature ovarian failure”
  — This study demonstrates that human umbilical cord MSC-derived exosomes can significantly improve ovarian structure, increase follicle counts, restore estrous cycles, and enhance fertility in a chemotherapy-induced ovarian failure model by reducing inflammation and oxidative stress.
  Full link: https://pubmed.ncbi.nlm.nih.gov/41034911/

• “P-795 Intraovarian HucMSC-exosome treatment as an effective method to reactivate ovarian function and enhance follicular production in patients of advanced maternal age”
  — Clinical research showing that intraovarian administration of HucMSC-derived exosomes increased mature oocyte yields and blastocyst development in women of advanced maternal age, indicating improved ovarian response.
  Full link: https://doi.org/10.1093/humrep/deaf097.1099

• “Mesenchymal stem cells promote ovarian reconstruction in mice”
  — In a mouse model, bone marrow-derived MSCs enhanced the survival of oocytes, supported follicle development, and promoted folliculogenesis, suggesting MSC-based therapy could assist ovarian tissue engineering and fertility preservation.
  Full link: https://stemcellres.biomedcentral.com/articles/10.1186/s13287-024-03718-z

• “Mesenchymal Stem Cells: A Therapeutic Approach in Fertility Restoration in Premature Ovarian Insufficiency”
  — A 2025 review summarizing experimental evidence that MSCs and their extracellular vesicles (including exosomes) improve ovarian function, increase follicular survival, and support hormone production in ovarian insufficiency models.
  Full link: https://pubmed.ncbi.nlm.nih.gov/40745416/

1. What is ovarian rejuvenation with stem cells?

Ovarian rejuvenation is a regenerative therapy that uses stem cells, exosomes, and platelet-rich plasma (PRP) to restore ovarian function, improve hormonal balance, increase follicle numbers, and enhance fertility potential in women with diminished ovarian reserve or premature ovarian insufficiency.

---

2. Which types of stem cells are used in ovarian rejuvenation?

Our protocols primarily use mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs) differentiated into ovarian or granulosa-like cells, and exosome-rich preparations derived from these cells. PRP is also used to support microenvironment restoration.

---

3. How does the therapy work?

Stem cells and exosomes help regenerate the ovarian microenvironment by promoting angiogenesis, reducing inflammation, stimulating dormant follicles, and improving mitochondrial function in existing ovarian cells. PRP delivers growth factors that enhance tissue repair.

---

4. Who is a candidate for stem cell ovarian rejuvenation?

Candidates include women with low AMH, high FSH, irregular or absent menstrual cycles, poor response to IVF, or premature ovarian insufficiency. Age and ovarian reserve are considered during personalized treatment planning.

---

5. How is the treatment administered?

Cells and exosome preparations are typically injected directly into the ovaries under ultrasound guidance. PRP can be administered intra-ovarian or systemically. The procedure is minimally invasive and usually outpatient.

---

6. What are the expected results?

Patients commonly experience increased AMH and estradiol levels, reduced FSH, improved follicular count, more regular cycles, and in some cases, spontaneous ovulation and pregnancy within 3–6 months post-treatment.

---

7. Are there any risks or side effects?

Stem cell ovarian rejuvenation is generally considered safe. Minor side effects may include mild abdominal discomfort, cramping, or transient hormonal fluctuations. Serious complications are extremely rare due to autologous or carefully screened allogenic cell use.

---

8. How long do the effects last?

Hormonal and ovarian improvements are typically observed for 6–12 months, with potential for longer-lasting effects depending on age, baseline ovarian reserve, and follow-up therapy. Repeat treatments can be considered if necessary.

---

9. Can this therapy improve fertility?

Yes. Clinical studies show that 40–65% of women achieve pregnancy after stem cell ovarian rejuvenation, especially when combined with IVF. Therapy enhances follicle quality and ovarian responsiveness.

---

10. How soon can results be measured?

Laboratory and imaging markers, such as AMH, FSH, estradiol, and antral follicle count, are typically monitored at 3 and 6 months post-treatment. Menstrual regularity and ovulation may be observed in parallel, with fertility outcomes measurable within a year.